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Can mid-infrared biomedical spectroscopy of cells,
ﬂuids and tissue aid improvements in cancer
survival? A patient paradigm
Caryn Hughes*a,b and Matthew J. Baker*b
This review will take a fresh approach from the patient perspective; oﬀering insight into the applications
of mid-infrared biomedical spectroscopy in a scenario whereby the patient presents with non-speciﬁc
symptoms and via an extensive diagnostic process multiple lesions are discovered but no clear sign of the
primary tumour; a condition known as cancer of unknown primary (CUP). With very limited options to
diagnose the cancer origin, treatment options are likely to be ineﬀective and prognosis is consequentially
very poor. CUP has not yet been targeted by infrared biospectroscopy, however, this timely, concise dis-
semination will focus on a series of research highlights and breakthroughs from the ﬁeld for the manage-
ment of a variety of cancer-related diseases – many examples of which have occurred within this year
alone. The case for integration of mid-infrared (MIR) technology into clinical practice will be demon-
strated largely via diagnostic, but also therapeutic and prognostic avenues by means of including cytologi-
cal, bio-ﬂuid and tissue analysis. The review is structured around CUP but is relevant for all cancer
diagnoses. Infrared spectroscopy is fast developing a reputation as a valid and powerful tool for the detec-
tion and diagnosis of cancer using a variety of sample formats. The technology will produce data and
tools that are designed to complement routine clinical practice; enhancing the ability of the clinician to
make a reliable and non-subjective decision and enabling decreased levels of mortality and morbidity and
gains in patient quality of life.
Introduction
Imagine the scenario of an individual who presents with non-
specific symptoms including a loss of appetite, unexplained
weight loss, constantly lethargy and breathlessness. All the
symptoms can be caused by conditions other than cancer, but
the GP makes a referral to hospital for tests and for specialist
advice. Following exhaustive analysis of medical history, full
blood count, urinalysis, stool occult, imaging including chest
X-ray computed topography of the thorax, abdomen and pelvis
and well as mammography, magnetic resonance imaging and
position emission topography, there was evidence of meta-
static growths throughout the body, but a failure in detection
of the primary tumour.1 In this situation, the patient is diag-
nosed with a cancer of unknown primary (CUP) following an
extensive diagnostic pathway.
CUP ranks among the 10 most common malignancies in
developed societies, accounting for 3–5% of incidence in both
genders.1 The clinical presentation of CUP is extremely hetero-
geneous. Patients are known to present with a single sight of
involvement such as the liver, bone, lung or lymph nodes.
However, over half of patients present with multiple sites of
involvement.2 Cancer Research UK reported data of 10 470
cases of CUP in 2010 broken down into four classifications in
order of incidence rate 1 Malignant neoplasm without specifi-
cation of site, 48%; 2 Secondary malignant neoplasm of respir-
atory and digestive organs, 32%; 3 Secondary malignant
neoplasm of other sites, 12%; 4 Secondary and unspecified
malignant neoplasm of lymph nodes, 9%. 1 relates to cases
where there has been insuﬃcient information to determine
the site of primary origin, whereas (2–4) are cases where 1 is
true but secondary malignancies have been located. (For full
information on CUP breakdown see http://www.cancer-
researchuk.org/health-professional/cancer-statistics/statistics-by-
cancer-type/cancer-of-unknown-primary). Interestingly, inci-
dence rates diﬀered when broken down across UK region (the
most common class in Wales and Northern Ireland was 3).
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Arguably CUP present the most challenging of diagnostic
situations and patient survival rates are extremely poor. It is of
great importance to determine the cell lineage and likely
primary sites of the cancer as tumours are amenable to dis-
tinct therapies. A personalised medicine approach may also be
key to identifying favourable or treatable subsets of patients.
In order to improve cancer survival rates in general, we
must adapt new and eﬀective technologies to complement
existing methods for faster and more reliable detection or
chemotherapeutic analysis. Mid-infrared (IR) spectroscopy cap-
tures the energies of fundamental vibrational modes of bio-
logical molecules that generally lie within the range of
400–4000 cm−1, a spectral region corresponding to mid-infra-
red (mid-IR) electromagnetic radiation. The method involves a
non-destructive and label-free process to probe the compo-
sition of the chemical environment of the sample, resulting in
a unique fingerprint of global biochemistry.
CUP is yet to be targeted by the clinical mid-infrared spec-
troscopy community however pioneering research has been
performed in diagnosis and prognosis of primary and second-
ary cancers. For a case where there is no clear answer as to
where the site of primary malignant origin may have occurred,
by analysing the biomolecular fingerprint for cases of known
secondary sites, IR spectroscopy could potentially oﬀer indica-
tive spectral biomarkers for diagnostic or prognostic out-
comes. CUP does ultimately present as challenging target for
the future of the field; in order to oﬀer a glimpse of the poten-
tials for improving the ominous outlook of CUP using mid-IR
biomedical spectroscopy, breakthrough milestones and
advances will be highlighted out of the extensive research
carried out in the field on multiple cancer targets.
Diagnostics: strategies for early
detection
It has been reported that cancer patient outcomes in the UK
are considerably lower than in other western countries.3,4
Numerous delays can occur to the patients primary and
secondary care; however, delays in symptomatic cancer diagno-
sis play a major role leading to more advanced stages of
disease at diagnosis. In 2010 the National Patient Safety
Agency (NPSA) published a review entitled ‘Delayed diagnosis
of cancer: Thematic review’ presenting findings where
patient safety incidents relating to actual or potential delayed
cancer diagnosis. The types of patient safety incident were
classified as 53% diagnostics (41% pathology, 12% radiology).5
There is therefore, a considerable requirement to make
interventions in order to minimise delays and lead to earlier-
stage diagnosis.
MIR biomedical diagnostics oﬀers numerous platforms in
which cells, fluids or tissue can be probed, label-free, in order
to achieve a potentially rapid and clinically relevant result. In
the case of CUP, early detection is not possible; there are no
current screening programmes. Analysis of blood provides an
ideal starting point for rapid and minimally invasive sample
collection. A patient with CUP may undergo a variety of
diﬀerent blood tests for tumour markers to suggest a certain
type of cancer, including prostate-specific antigen (PSA) (pros-
tate), human chorionic gonadotrophin (HCG) (germ cell),
CA19-9 (pancreas/bile ducts) and CA125 (ovarian). It is well
known, however, that many of these markers are not comple-
tely reliable; PSA for is example is notorious for generating
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false positive results6 and although CA125 is the gold standard
tumour marker in ovarian cancer however, diﬀerent studies
have reported contradictory results.7
Attenuated Total Reflection-Fourier Transform Infra Red
(ATR-FTIR) spectroscopy is gaining increasing acceptance as a
reliable diagnostic tool for detecting cancer using blood based
samples and there have been a number of breakthrough
examples. Gajjar et al.8 have previously demonstrated such an
application to distinguish ovarian and endometrial cancer
against non-cancer controls with classification accuracies of
up to 96.7% and 81.7% respectively. More recently Lima et al.9
have extended this research to exploitation of IR spectral bio-
markers derived from blood plasma or serum analysis to evalu-
ate ovarian cancer stage and type. Remarkably, in a case study
for stage I vs. stage II–IV (plasma samples), they reported accu-
racies of 100% sensitivity and specificity based on the use of
33 spectral features.
The use of ATR-FTIR is certainly a tangible accessory for
rapid point of care diagnostics; its operation is simple and
requires minimal sample preparation, especially for bio-
fluids.10 Hands et al. have recently reported an FTIR-ATR
based diagnostic test for brain cancer that is achievable within
4 minutes.11 They reported that, when used in conjunction
with a complementary Bioplex immunoassay, taking 4 hours
to complete, a dual result can be made available within a total
of 5 hours from sample collection. Furthermore, during a sep-
arate study, they were also able distinguish between gliomas
(high-grade and low-grade) from non-cancer with an average
sensitivity of 93.75% and specificity of 96.53% from blood
serum samples of 97 patients.12
In addition to point of need applications, FTIR spec-
troscopy can also be utilised for high-throughput (HT) diag-
nostic screening. Ollesch et al.13 have demonstrated such
methodology for blood samples of urinary bladder cancer
(UBC) patients where robotically prepared thin dried film for
measurements in transmission mode. They were able to
achieve a sensitivity of 93 ± 10% and a specificity of 46 ± 18%
for bladder cancer (low specificity was most likely attributed to
the unbalanced and small number of control samples).
Investigations of specific cell types are also important for
new diagnostic pathways. For example, peripheral blood mono-
nuclear cells (PBMCs) present a new route for cancer detection
based on the immune system response to the presence of
tumour, rather than on observation of the tumour cells them-
selves.14 Zelig et al. have recently evaluated the feasibility of
this approach for early detection of breast cancer. The results
provide evidence that the PBMCs of patients with breast
cancer are biochemically distinct from the PBMCs of healthy
subjects, including patients with benign tumours, with no sig-
nificant diﬀerences in PBMC spectra between patients with
benign tumours and healthy subjects.
Although there are no specific examples of MIR spec-
troscopy applied to patients with non-specific symptoms and
CUP patient samples, much can be learned, however, from the
recent breakthroughs for other cancer targets. During diagno-
sis is it essential to determine specific cell lineage, such as
lymphoma, sarcoma or melanoma in order to make a more
informed therapeutic decision. The issue with CUP is that the
tumours are often poorly diﬀerentiated. This is also an issue
for as certain primary tumour sub-variants and sometimes it is
often not possible to tissue architecture or cell morphology
alone. Fortunately, however, there are have been many MIR-
based in vitro studies that have been performed on sub-var-
iants of cancers that have shown it is possible to discriminate
between cell types using the spectral bio-fingerprint;15,16
despite situations where the overall cell morphology is not
necessarily distinctly unique. Previous studies have inferred
that spectral abnormalities have been observed not only
detectable in malignant cervical scrapings but also in those
with the premalignant condition cervical dysplasia.17 Town-
send et al. have recently conducted an IR study on cervical
cytological samples (Fig. 1) concluding that MIR spectroscopy
indeed can distinguish truly normal cells and cells with
normal morphology from the vicinity of abnormalities. During
this study, despite, in some cases cells being pathologically
diagnosed as healthy squamous, their spectra suggested other-
wise, displaying early spectral markers of disease18
A pathological diagnosis using a tissue biopsy will typically
involve the use immunohistochemical/immunofluorescent
stains and observation of tissue architecture; a laboriously
manual method used for over 150 years, relying on human
decision-making.19 Tissue can be imaged with mid-infrared
spectrometers coupled to a microscope with a focal plane array
detector, creating a stain-free, global molecular fingerprint
within a spatially-resolved hyperspectral map. This can be per-
formed on both formalin fixed paraﬃn embedded (FFPE)
tissue (either dewaxed20 or still embedded in paraﬃn wax21) or
snap-frozen tissue. Typically analysis of tissue using this
method involves identification of tissue structures (such as
epithelial, stroma, blood, bone) before diagnosis in terms
healthy, benign, malignant and/or extent of malignancy.22
Fig. 1 40× visual images of annotated cells some diﬀerent pathological
groups: (top) squamous SQ), (middle) Barrett’s Esophageal (BE) and
(bottom) dysplasia (DYS). Using an artiﬁcial neural network classiﬁcation
of IR spectral data sensitivities and speciﬁcities of 95.5% and 94.7% (BE
vs. SQ), 88.7% and 91.4% (BE vs. DYS) and 93.4% and 90.0% (SQ vs. DYS)
were reported. Adapted with permission from [ref. Townsend et al.18].
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Bird et al.23 have previously shown that for lung cancer,
MIR biomedical spectroscopy can distinguish major classes
(adenocarcinoma, squamous cell carcinoma, small cell carci-
noma and bronchioloalveolar carcinoma). Specifically, this can
be achieved with high sensitivity, specificity and accuracy for
small cell carcinoma vs. non-small cell carcinoma (91.2%,
98.0% and 94.6%) but low sensitivity, specificity and accuracy
for adenocarcinoma vs. bronchioloalveolar carcinoma (88.8%,
47.2% and 68.0%). Similarly, Großerueschkamp et al. recently
presented (Fig. 2) the ability to discriminate between small
cell, hamartochondroma, squamous cell, carcinoid, pleura
mesothelioma, adenocarcinoma, thymoma and inflammation/
necrosis but were able to perform adenocarcinoma subtyping
(acinar, lepidic, papillary and micropapillary)24 as Akalin
et al.25 have also reported similar findings and as aforemen-
tioned, the diﬀerentiation of subtypes is especially important
for prognosis and therapeutic decision.
As a further example, transitional cell carcinoma (TCC),
accounting for 85–90% of all epithelial tumours of the bladder
and urinary collecting system, is heterogeneous with a pro-
nounced ability for divergent diﬀerentiation and has many
sub-variant phenotypes as a consequence. Tissue structure dis-
crimination IR-Imaging has also been successfully applied to
TCC and its sub-variants such as clear cell, which is diﬃcult to
identify in poorly diﬀerentiated carcinoma of the upper tract.26
Until recently, one of the limiting factors in IR imaging has
been the limited pixel resolution (typically ∼5.5 μm). Although
higher magnification optics have previously been available, the
use of non-customised objectives, have generally resulted in
extremely poor SNR making them unsuitable for routine appli-
cations. The most advanced focal plane array setup with a syn-
chrotron-source in terms of pixel resolution was developed at
the IRENI beamline (Synchrotron Radiation (SR) Center, WI,
USA) which combined 12 separate SRIR beam to enable diﬀr-
action-limited imaging using a pixel size of ∼0.5 μm, allowing
for subcellular chemical imaging.27–29 Now, however, high
definition (HD) IR imaging is more routinely possible on a
bench-top FTIR spectrometer, achieving a pixel resolution of
∼1.1 μm using a standard thermal source.30,31 For some clini-
cal applications, a pixel resolution of ∼5.5 μm would be appro-
priate for cytological screening when isolating single cell
spectra from cultured cells as demonstrated by Mazur et al.32
and Filik et al.33 However, for instances where there may be a
clinical requirement to isolate the IR signature of single cells
condensed within a tissue cross-section where cells therefore
appear smaller in magnitude, increasing the eﬀective pixel size
is of use to more accurately resolve the cells spatially and to
reduce ‘pixel mixing’ eﬀects of neighbouring tissue structures.
The availability of benchtop instrument HD FT-IR imaging
is a very recent technological advancement and is an exciting
progressive step in terms of targeting and diﬀerentiating
cancer-related tissue sub-structure. As an example target,
lymph nodes are particularly important as immune response
initiators they are routinely used in diagnostic and prognostic
evaluations for cancer and chronic inflammation or infection.
In the case of the CUP patient, up to 10% of all neck lymph
node metastases present without a known primary site and the
optimal treatment strategy for these patients is still un-
defined.34 Evaluation of lymph nodes is often involved in
eﬀorts to attempt the determination of the primary site.
Lymph nodes are highly heterogeneous, however, due to a con-
stant stream of lymphocytes, macrophages, and antigen cells
ever present in the fibrovascular tissue. Excitingly, Leslie
et al.23 been able to demonstrate that cells of eight distinct
classes (naïve and memory B cells, T cells, erythrocytes, con-
nective tissue, fibrovascular network, smooth muscle, and
light and dark zone activated B cells) currently identifiable
only through immunohistochemical stains and manual reco-
gnition via optical microscopy, can be distinguished through a
single IR spectroscopic image; this was achievable for the first
time through the benefits of HD-IR imaging. Furthermore,
they were able to achieve this in healthy, reactive, and malig-
nant lymph node biopsies using a random forest classifier.
The advent of commercially available quantum cascade
laser (QCL) IR microscopes will only further enhance the diag-
nostic tool status of mid-infrared imaging. With this techno-
logy, the conventional thermal source in a benchtop IR system
has been exchanged with high-intensity tuneable lasers with a
customisable frequency range (Fig. 3). Coupled with a room-
temperature detector, high definition IR images can be col-
lected allowing the operator to scan faster (in discrete fre-
Fig. 2 Using IR imaging and random forest classiﬁers to discriminate
between (a) small cell cancer (cyan), (b) hamartochondroma (yellow), (c)
squamous cell carcinoma (olive), (d) carcinoid (magenta), (e) pleura
mesothelioma (red), (f ) adenocarcinoma (pink), and (g) thymoma (light
green), and inﬂammation/necrosis (blue and dark green). Adapted with
permission from [ref. Großerueschkamp et al.24].
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quency mode) and for longer (without the time-limit worry
associated with the eventual warming of typical FTIR spectro-
meter detectors cooled at cryogenic temperatures).35–38
Therapeutic: personalised treatment
Optimal therapeutic management of patients with CUP
remains controversial as there is a lack of randomized studies
comparing diﬀerent treatment options and as a result, treat-
ment is mainly based on non-randomized evidence and insti-
tutional policy. Recommendations include surgery alone,
radiotherapy with or without concomitant chemotherapy.
However, the morbidity and quality of life cost of these com-
bined treatments may be high. No randomized or prospective
studies are currently available to specifically support these
approaches and such a study may be diﬃcult to undertake, as
this disease is rare.39
If a patient was able to benefit from personalised oncology,
a resolved indicative signature of chemosensitivity could have
the power to guide treatment decisions. The genomics revolu-
tion has great potential and a genomic signature that can
predict a patient outcome is revolutionary, but it is still early
days and there have been very few assays that have come out of
the genomics revolution in the last 12 years.40 In addition to
genetic mutation analysis, cellular chemosensitive assays
grown from primary patient cells could also be used as a treat-
ment-guiding tool.
There have been many in vitro based infrared studies of
chemotherapeutic action on cancer cell lines which has
involved both single point measurements and FPA imaging of
chemically fixed and dried cells.41–46 As a clinical example,
Zelig et al. have used FTIR spectroscopic markers of leukaemia
in peripheral blood mononuclear cells (PBMCs) for initial pre-
screening and follow-up of individual patient response to
chemotherapy.47 They were able to follow progression during
chemotherapy largely based on lipid IR absorptions, which
have been demonstrated as a spectral marker of apoptosis.48,49
They were unable to predict the treatment outcomes based on
the PBMC spectra obtained in pre-treatment days, however, it
was shown that FTIR spectroscopy could provide additional
information on chemotherapeutic response of an individual
patient basis; an application that may be vital to identify un-
expected complications in real time as soon as they may
appear during treatment.
In a similar fashion to cytotoxic assays used in drug discov-
ery, there is a lack of appropriate in vitro models that have the
capability to predict the chemotherapeutic response for each
patient. In vitro models often fail to predicting in vivo eﬃcacy
of specific chemotherapeutic agents and are thus starting to
be replaced by multicellular tumour spheroid (MTS) models
that more realistically reflect the behaviour of cells in tumour
tissues.50 In terms of IR research in this area, Smolina et al.
recently reported direct comparison of cell phenotypes using a
triple-negative breast cancer cell line, MDA-MB-231 grown in
either standard two-dimensional (2D) or 3-dimentional (3D)
laminin-rich extracellular matrix (lrECM) culture (Fig. 4).51 In a
comparison with spectra of carcinoma cells from clinical
patient samples, principal component analysis (PCA) indicated
a separation between the 2D versus the 3D and clinical scores
across the first principal component. While cell lines will
never have phenotypes absolutely identical to those found in
tissues, it does show promise that, as an early deduction,
chemosensitivity may possibly be inferred in cells harvested
from clinical biopsies of a suspected phenotype via correlation
with features in 3D cultured cell lines of known phenotype.
Ruppen et al.52 have recently reported on the design of a
microfluidic device that is able to form single spheroids of
uniform size from either cell line or a limited number of
human primary cells thus pinpointing an exciting direction of
personalized oncology and live cell analysis would be a great
advantage. Single cell IR measurements in the aqueous
environment have initially benefitted by the use of ultrabright
synchrotron radiation sources due to the fact that transmission
measurements in an aqueous environment are constrained by
the strong IR absorption of water which consequentially
Fig. 3 (a) Schematic diagram of the QCL-based Spero spectral imaging microscope shown for transmission mode. The system also operates in
reﬂection mode. (b) Plot illustrating the tunable ranges of the 4 individual QCLs providing continuous coverage of the 900–1800 cm−1 wavenumber
range. Adapted with permission from [ref. Bassan et al.36].
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decreases light throughput.53,54 Chan and Kazarian, however,
have recently pioneered IR imaging of live cancer cells in the
natural aqueous environment by ATR-FTIR using a regular
benchtop thermal source and were able to monitor fine chemi-
cal and physical changes in situ with very fast acquisition time,
good spatial resolution and high molecular specificity.55 Fur-
thermore, Marcsisin et al. have demonstrated that with even
without ATR or a synchrotron source, the use of live cell FTIR
imaging can produce interpretable spectral diﬀerences from
live cells treated with chemotherapeutic drugs with optimised
instrumentation and data processing methodology.56 The
ability to collect data on a commercially available system with
no required modification increases the potential to integrate
the technology more easily into the clinical setting. The data
processing methodology means that a larger quantity of cellu-
lar data can be acquired at a faster rate without compromising
on spectral quality, therefore allowing results to be more stat-
istically meaningful.
Prognosis: risk of progression/
recurrence
Metastatic spread is generally considered the final step of
tumour progression, however this is not necessarily the case
for CUP. There are at least two diﬀerent hypotheses which
attempt to explain CUP biology; CUP are a heterogeneous
group of site-specific tumours which share the properties of
the small primary from which they derive, or conversely, CUP
are a distinct biological entity that involve specific genetic and
phenotypic alterations. At present, there are no known and
validated molecular features to clearly distinguish these
cancers, making them again an ideal target for assessment by
MIR spectroscopy.57
There is MIR spectroscopic evidence to suggest tumour pro-
gression to the metastatic state involves structural modifi-
cations in DNA that are markedly diﬀerent from the
modifications associated with the formation of the primary
tumour.58 Cancer cells acquire cell-autonomous capacities to
undergo limitless proliferation and as a result are thought to
require the support of the tumour microenvironment (TME)
(containing carcinoma-associated fibroblasts, leukocytes, bone
marrow-derived cells, blood and lymphatic vascular endo-
thelial cells) in order to progress.59 In a controlled study,
Ukkonen et al. recently identified the influence of cancer cells
in the TME using MIR imaging of an in vitro myoma organo-
typic model with invading melanoma and oral tongue carci-
noma cell lines. They determined that amide and collagen
triplet absorption regions could serve as spectral markers for
cancer-induced modifications in the TME.60
These preliminary results are also supported by an indepen-
dent MIR imaging study applied to histopathological speci-
mens of breast cancer of diﬀerent tumour histological
grades.61 MIR spectral changes were observed when examining
the extracellular matrix close to and far from carcinoma, in
particular in the relative intensities of the collagen bands at
1640 and 1630 cm−1 illustrated a change in collagen spectral
features while moving away from the tumour (Fig. 5). These
results support the notion that the 1700–1600 cm−1 spectral
range could be used as spectral markers to identify cancer-
induced modifications in the TME.
There will be some cancers that can be managed via waitful
watching or active surveillance. Active surveillance is suitable
when the cancer is considered to be in the early stages and
localised. It usually involves regular hospital tests, such as
biopsies and MRI scans (waitful watching requires less fre-
quent tests). There are a number of reasons why it may be the
case not to intervene with aggressive chemotherapy of radical
surgery. As a primarily age-related disease it is sometimes wise
not take drastic measures in attempt to neutralise the risk due
to the change of considerably aﬀecting quality of life; in the
case of prostate cancer, for example, there is an element of
overtreatment in lower risk patient cohorts.62 Certainly, in
terms of prognostic markers, much more research still needs
to be done. The integration of gene expression, immunohisto-
chemistry, magnetic resonance imaging and tissue mor-
phology has met with limited success and as yet there is no
widespread clinical acceptance. While much progress has been
made in diagnostic applications of MIR biospectroscopy, there
are very few reports of prognostic capability; naturally as it is
such a challenging area. In an exciting breakthrough reported
this year, Kwak et al.63 have shown that a tissue-based IR spec-
tral pathology approach outperforms Kattan nomogram and
CAPRA-score for predicting risk of recurrence in mid-grade
dominant cases of prostate cancer. They also determined that
Fig. 4 Bright-ﬁeld microscopy (A, B, D, E) and IR (C, F) images of adja-
cent 4 μm-thick sections of MDA-MB-231 breast cancer cells grown in
2D (A–C) and 3D (D–F) cultures. For 2D culture, image A shows the H&A
stained section. The adjacent, unstained section is presented in image
B. The IR raw image (absorbance at 1654 cm−1) of the same region is
reported in image C. For the 3D culture, image D shows the H&A stained
section. The adjacent, unstained section is presented in image E, and the
IR raw image (absorbance at 1654 cm−1) of the same region is reported
in F. One covers an area of 180 × 180 μm2. Adapted with permission
from [ref. Smolina et al.51].
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an IR score has a truly independent predictive power; a com-
bined score (IR + Kattan + CAPRA-S) was not able to signifi-
cantly improve upon the use of IR score alone.
Knowledge of the underlying factors of tumour recurrence
is also not fully understood. Over the last few decades,
a number of hypotheses have been proposed including clonal
selection and angiogenic dormancy. More recently the cancer
stem cell (CSC) hypothesis64 has sparked controversial option.
CSCs are believed to persist in tumours as distinct populations
that are fundamentally associated with drug resistance,
tumour recurrence, and metastasis. Assessment of CSCs via
standard techniques in molecular biology often require large
quantities of cells (often to the power of 105/6), however, yet IR
spectroscopy oﬀers a unique opportunity to study and charac-
terise CSCs on the single cell level which may help to increased
understanding of the cancer pathology.65,66 Moreover, the
migration ability of CSCs have also been proposed to explain
the non-existence of the primary cancer in CUP25 and in for
many cancers CSC-targeted therapeutic strategies for thera-
peutic treatment are being assessed.67 As discussed in the pre-
vious section, there would also be an opportunity for MIR
spectroscopy to serve as an investigative tool for therapeutic
research.
Conclusions
Many milestones and improvements have been made not only
in the technology but also in fundamental understanding of
the MIR techniques. As demonstrated, in countless examples
of research across cell fluid and tissue investigations, the
ability to distinguish between non-cancer and cancer states
using label-free infrared spectral biomarkers is undeniable.
The number of oncological research applications will inevita-
bly rise as a result and hopefully the field will become increas-
ingly internationally recognised and accepted.
Fig. 6 Schematic of the potential use of FTIR in the patient’s clinical journey (adapted and updated from [ref. Dorling and Baker69]).
Fig. 5 Analysis of a breast tissue sample. (A) H&E stained section of
breast tissue showing the extracellular matrix on the left and a
mammary duct invaded by grade 2 carcinoma cells on the right. (B and
C) Images generated by discriminant partial least squares. The ratio of
intensities at 1630/1640 cm−1 is used in (C) for sub-classiﬁcation of col-
lagen (light to dark). (D) Mean second derivative spectra taken from the
three areas a, b, and c indicated in (C) corresponding to far-from-
tumour collagen (a), close-to-tumour collagen (b) and to the cells
present inside the tumour region (c). Adapted with permission from [ref.
Kumar et al.61].
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For the CUP and for non-symptomatic patients, outlook is
currently very poor in terms of diagnostic, therapeutic and
prognostic options. It is evident, as demonstrated by the
breadth and success of oncological research in this review, that
MIR spectroscopy is on course to be a major authoritative tool
in oncology. Fig. 6 portrays a schematic of the potential use of
MIR throughout the patient’s clinical journey. As a positive pro-
spect, the limitations of the MIR biomedical spectroscopy could
be tested by playing a significant role in CUP research; along-
side the advent of modern molecular techniques such as DNA,
gene expression profiling and proteomics.
MIR biomedical spectroscopy has recently gained signifi-
cant recognition as part of the creation of the government-
funded Clinical Infrared and Raman Spectroscopy for Medical
Diagnosis Network68 which is a step forward in gaining clinical
acceptance. In order to realise the goal of translating bio-
medical spectroscopy benefits to address unmet needs in
oncology, however, great eﬀorts must be made on behalf of
academic, industrial and clinical partners in order to secure
its place in the clinical environment. As demonstrated, proof
of the concept has been demonstrated in many small but con-
trolled studies and clinically significant results are required to
truly capture the interest of healthcare practitioners. Reaching
this next plateau, therefore, requires the pooled community to
consider sample size and power in clinical trials. Finally, as
commercialisation is key to translating the science to the
clinic, industrial partners will then be more likely to enter
these untapped markets in the clinical and life sciences,
making FTIR spectroscopy-based healthcare products and ser-
vices a reality.
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